Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.47 |
| ▸ | PPP5C | P53041 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 8/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016622 | 0.84 | GBA1 (0.45) | GBA1PPP5C | |
| SCHEMBL533902 | 0.77 | GBA1 (0.50) | GBA1PPP5C | |
| SCHEMBL19549582 | 0.77 | GBA1 (0.46) | GBA1PPP5CPPARG | |
| SCHEMBL15470821 | 0.76 | GBA1 (0.48) | GBA1PPP5C | |
| SCHEMBL8969164 | 0.74 | EPHX2 (0.44) | GBA1PPP5CS1PR5S1PR1S1PR3 | |
| SCHEMBL8970509 | 0.74 | EPHX2 (0.44) | GBA1PPP5CS1PR5S1PR1S1PR3 | |
| SCHEMBL8970376 | 0.74 | EPHX2 (0.44) | GBA1PPP5CS1PR5S1PR1S1PR3 | |
| SCHEMBL8970086 | 0.74 | EPHX2 (0.44) | GBA1PPP5CS1PR5S1PR1S1PR3 | |
| SCHEMBL2606682 | 0.74 | PPP5C (0.46) | PPP5CS1PR5S1PR1S1PR3 | |
| SCHEMBL1298353 | 0.73 | PPARG (0.48) | S1PR5S1PR1S1PR3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206230-B2 | Benzylic compound | AJINOMOTO CO., INC. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20140371424-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-8859732-B2 | Benzylic compound | AJINOMOTO CO., INC. (JP) | 2014-10-14 | — | — | US | disclosed |
| EP-2518041-A1 | BENZYL COMPOUND | Ajinomoto Co., Inc. (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20110160433-A1 | BENZYLIC COMPOUND | AJINOMOTO CO., INC. (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160433-A1 | BENZYLIC COMPOUND | VIP, NGLY1, FURIN | GBA1 844/4885PPP5C 4416/4885S1PR5 2946/4885 |
| US-20140371424-A1 | BENZYLIC COMPOUND | VIP, NGLY1, FURIN | GBA1 844/4885PPP5C 4416/4885S1PR5 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.